Diffuse Large B-Cell Lymphoma

Individuals with relapsed or refractory lymphoma who received chimeric antigen receptor T-cell therapy experienced a wide range of adverse events compared with those who received other treatments, study results showed.

In this video, Jason Westin, MD, discusses the results of the Smart Stop trial, presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Individuals with private insurance that requires a signed agreement before receiving chimeric antigen receptor T cells had significant delays in treatment, study results presented at ASH Annual Meeting and Exposition showed.

SAN DIEGO — Significant racial and ethnic disparities exist in survival outcomes of adolescent and young adults with diffuse large B-cell lymphoma, according to study findings presented at ASH Annual Meeting and Exposition.

Chimeric antigen receptor T cells have improved survival rates as second-line therapy for individuals with high-risk diffuse large B-cell lymphoma, but available therapies lack cost-effectiveness at current prices, study results showed.

In this video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute discusses factors that may keep patients from necessary DLBCL care.

In a video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute discusses who benefits from awareness surrounding DLBCL.

NEW ORLEANS — Patients older than 80 years of age with diffuse large B-cell lymphoma more than tripled their overall survival when receiving at least six cycles of chemotherapy.

Nearly 30,000 new cases of diffuse large B-cell lymphoma are diagnosed annually in the United States.

Lisocabtagene maraleucel extended EFS and PFS compared with high-dose chemotherapy and hematopoietic stem cell transplant for relapsed or refractory large B-cell lymphoma, according to topline data released by the agent’s manufacturer.